- Home
- ATCX vs ICCM Comparison
ATCX vs ICCM Comparison
Compare ATCX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ATCX | ICCM |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Brazil | Israel |
| Employees | 13 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 20.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | ATCX | ICCM |
|---|---|---|
| Price | $2.60 | $3.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.75 | $2.50 |
| AVG Volume (30 Days) | 10.0K | ★ 75.6K |
| Earning Date | 03-16-2023 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $827,667.00 | $139.51 |
| Revenue Next Year | $166.45 | $75.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $0.13 |
| 52 Week High | $14.01 | $9.54 |
Technical Indicators
Market Signals| Indicator | ATCX | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 46.18 |
| Support Level | $2.79 | $2.71 |
| Resistance Level | $3.17 | $5.69 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 53.33 | 48.05 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.